Skip to main content

Table 5 Seroconversion rates from days 0 to 14 (ITT population)

From: A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Treatment group Patients seroconverted by day 14a n (N) Percentage 95% Confidence intervalb
IC43 100 μg with adj 52 (80) 65.0% (54.1%, 74.5%)
IC43 100 μg w/o adj 58 (72) 80.6% (70.0%, 88.0%)
IC43 200 μg with adj 54 (72) 75.0% (63.9%, 83.6%)
Placebo 5 (71) 7.0% (3.0%, 15.4%)
  1. aSeroconversion defined as ≥4-fold increase in Outer membrane protein F/I hybrid vaccine (OprF/I)-specific IgG antibody titer from days 0 to 14. b95% Confidence interval calculated according to Wilson’s method, as recommended by Altman [17]. ITT intention-to-treat, n number of patients seroconverted, N number of patients with data, w/o adj without aluminum hydroxide adjuvant, with adj with aluminum hydroxide adjuvant